Publikationen in Zusammenarbeit mit Forschern von University of Oxford (72)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. An atlas of cells in the human tonsil

    Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

  3. CD137 (4-1BB) and T-Lymphocyte Exhaustion

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

  4. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  5. Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

    BMJ Global Health, Vol. 9, Núm. 2

  6. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  7. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357

  8. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  9. Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 619-630

  10. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

  11. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

    OncoImmunology, Vol. 13, Núm. 1

  12. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  13. Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities

    Journal for immunotherapy of cancer, Vol. 12, Núm. 5

  14. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy

    Cancer Cell

  15. Tumor slice culture system for ex vivo immunotherapy studies

    Methods in Cell Biology (Academic Press Inc.)

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  4. Druggable Targets in Cytokine Release Syndromes

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4320-4322

  5. Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 23, pp. 4711-4727